---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104547"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:04:28.747490+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling

## Summary
- Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.
- Board changes effective Aug 7: Anne-Marie Martin and David Ryan resigned; Mittie Doyle and Andrew Allen appointed as Class I and II directors, respectively.
- CLN-978 Phase 1 studies in SLE, RA, and Sjögren's actively enrolling; initial SLE safety and B cell depletion data expected Q4 2025.
- Velinotamig (BCMAxCD3 T cell engager) in-licensed from Genrix Bio for $20M upfront; up to $692M in milestones plus tiered royalties.
- Partner Taiho plans to submit NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by end of 2025 based on REZILIENT1 pivotal data.

## SEC filing metadata
- accession: 0000950170-25-104547
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/0000950170-25-104547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/cgem-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104547
- JSON: https://secwatch.observer/filing/0000950170-25-104547.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.